CVGENES-AT-TARGET
Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention
| Coordinatore | DEUTSCHES HERZZENTRUM MUNCHEN
Organization address
address: Lazarettstrasse 36 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://cvgenesattarget.eu/ |
| Totale costo | 7˙875˙614 € |
| EC contributo | 5˙995˙449 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2016-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
DEUTSCHES HERZZENTRUM MUNCHEN
Organization address
address: Lazarettstrasse 36 contact info |
DE (MUNICH) | coordinator | 853˙354.30 |
| 2 |
UNIVERSITY OF LEICESTER
Organization address
address: University Road contact info |
UK (LEICESTER) | participant | 825˙270.00 |
| 3 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 609˙720.00 |
| 4 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 539˙488.30 |
| 5 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 503˙040.00 |
| 6 |
4SC DISCOVERY GMBH
Organization address
address: AM KLOPFERSPITZ 19A contact info |
DE (PLANEGG MARTINSRIED) | participant | 454˙260.00 |
| 7 |
BIOCEROS BV
Organization address
address: YALELAAN 46 contact info |
NL (UTRECHT) | participant | 446˙850.00 |
| 8 |
CLINICAL GENE NETWORKS AB
Organization address
address: Karolinska Sience Park - FOGDEVRETEN 2 contact info |
SE (STOCKHOLM) | participant | 397˙748.20 |
| 9 |
GENEDATA AG
Organization address
address: MARGARETHENSTRASSE 38 contact info |
CH (BASEL) | participant | 374˙062.50 |
| 10 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 354˙560.00 |
| 11 |
UNIVERSITAET ZU LUEBECK
Organization address
address: RATZEBURGER ALLEE 160 contact info |
DE (LUEBECK) | participant | 336˙080.00 |
| 12 |
Horizon Discovery Limited
Organization address
address: CAMBRIDGE RESEARCH PARK contact info |
UK (Cambridge) | participant | 240˙179.20 |
| 13 |
EUROPEAN SCREENINGPORT GMBH
Organization address
address: SCHNACKENBURGALLEE 114 contact info |
DE (HAMBURG) | participant | 60˙836.50 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors. More recently, results of genome-wide association (GWA) studies added to our perception of mechanisms leading to atherosclerosis. At present, over 40 CAD and several genomic risk loci have been identified, the majority through efforts led by the applicants. Some genes at these loci work through known risk factors such as lipids and, in fact, are already established or evolving treatment targets. However, this is not true for the majority of risk variants, which implies that key pathways leading to atherosclerosis are yet to be exploited for therapeutic intervention. This EU network (CVgenes@target), which brings together an equal number of SME- and academic partners, will utilize genomic variants affecting atherosclerosis risk for identification of both underlying genes and affected pathways in order to identify, characterize, and validate novel therapeutically relevant targets for prevention and treatment of CAD and stroke. In programme 1 we will investigate molecular mechanisms at the genomic loci in order to further unravel causal genes, in programme 2 we will explore in vitro and in vivo whether the pathways disturbed by causal genes are suitable for therapeutic intervention, and in programme 3 we will establish assays and initiate high throughput screens to tackle therapeutically attractive targets. Our resources including large OMICs and state-of-the-art bioinformatics platforms as well as multiple, already established in vitro and in vivo models support the feasibility of the approach. In fact, two genomic risk loci (ADAMTS7 (CAD); HDAC9 (stroke and CAD)), both identified in GWA studies under direction of the applicants, already revealed attractive targets for therapeutic intervention.'
Altri progetti dello stesso programma (FP7-HEALTH)
DIAGMAL (2013)
Translation of the direct-on-blood PCR-NALFIA system into an innovative near point-of-care diagnostic for malaria
Read MoreEU-LAC HEALTH (2011)
Defining a Roadmap for Cooperative Health research between the EU and Latin America-Caribbean countries: a Policy Oriented Approach
Read MoreEECALINK (2009)
Promotion and facilitation of international cooperation with Eastern European and Central Asian countries
Read More